Healthcare, Pharma & Life Sciences

PARIS – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) reported that its 12-lipoxygenase inhibitor CAD-1005 reduced new or worsening thrombotic events by more than 25 percentage points versus placebo in a Phase 2 trial in heparin-induced thrombocytopenia (HIT), with 50% of treated patients affected versus more than 75% on placebo. The data were presented as one of three late-breaking abstracts at the ISTH 2026 Congress in Paris.

Trial is first randomized, blinded, placebo-controlled study in HIT

Principal Investigator Dr. Steven E. McKenzie delivered the oral presentation, which Cadrenal describes as the first randomized, blinded, placebo-controlled trial in HIT patients. CAD-1005 was formerly known as VLX-1005. The study was not sufficiently powered for statistical significance.

Ponte Vedra, Fla. – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has launched a structured process to secure out-licensing, portfolio monetization or co-development partners for its late-stage cardiovascular assets, after grouping them into a Cardiac Acute Critical Care Franchise.

The company is exploring development, licensing and commercialization deals for CAD-1005, frunexian and tecarfarin. It describes the approach as capital-efficient and says it is shifting to a partnership-driven business model.

PONTE VEDRA, Fla. – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) reached agreement with the FDA on the primary endpoint and placebo-controlled design of its Phase 3 registration study of CAD-1005, a first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT). The agreement came at a Type D meeting held July 28, 2026.

FDA accepts thrombus-extension definition of worsening HIT

The agency agreed to define worsening HIT as progression of thrombotic events through Day 14 of treatment or hospital discharge. Worsening will also include extension of an existing thrombus into a new vascular segment or bed. Cadrenal said this avoids site-to-site variability from manual size measurements.

The composite primary endpoint will measure the proportion of Serotonin Release Assay-positive (SRA+) participants with adjudicated new or worsening composite thromboembolic events through Day 14 or hospital discharge.

Ponte Vedra – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) will put CEO Quang X. Pham in front of investors at 10:15 a.m. ET on Tuesday, September 29, 2026, with a webcast presentation at the Lytham Partners Fall 2026 Investor Conference.

Two-day virtual conference includes one-on-one investor meetings

The conference runs virtually on September 29-30, 2026. Management will hold one-on-one meetings throughout the event. Investors can arrange them through Lytham Partners or by registering for the conference. A replay of the webcast will be available after the event.

CAD-1005 holds FDA and EMA designations in heparin-induced thrombocytopenia

Cadrenal describes itself as a late-stage biopharmaceutical company focused on critical care cardiology and orphan cardiovascular conditions. Its pipeline includes CAD-1005, tecarfarin and frunexian.

PONTE VEDRA, Fla. – – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) has opened a formal strategic process covering its entire four-asset pipeline, with options ranging from asset sales to a full business combination. The Board of Directors initiated the review to maximize value for shareholders, and Tungsten Advisors will act as exclusive strategic financial advisor.

Four programs, from Phase 3-ready to preclinical, are in scope

The review covers CAD-1005, tecarfarin, frunexian and CAD-2000, the company's second-generation 12-LOX platform. Cadrenal says the process builds on ongoing partnering discussions.

Potential transactions include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions and business combinations.

United States – October 26, 2026 -- The direct-to-consumer cash-pay market in biopharma could reach $26 billion at its peak, according to Morgan Stanley healthcare services analyst Erin Wright, as U.S. patients take more control over how they access and pay for care.

GLP-1 obesity drugs show a branded product can run half its volume through consumer-led access

A branded prescription product in the GLP-1 market could support roughly half of its volume through a consumer-led access pathway, the analysis says. Patient demand for obesity treatment built before insurers were ready to pay for it. Patients can now choose a treatment, find a price within budget, obtain a digital prescription and fill it through a manufacturer-selected pharmacy or fulfillment partner. Many large-cap biopharma companies now operate direct-to-consumer platforms.

United States – October 25, 2026 -- The Centers for Medicare & Medicaid Services (CMS) will replace its single annual window for HCPCS Level II code applications with quarterly cycles for drugs and semi-annual cycles for devices, Administrator Seema Verma said at the Medical Device Manufacturers Association (MDMA) Annual Meeting.

CMS expects faster adoption for new technologies under the revised coding calendar

Until now, applicants for new HCPCS Level II codes had one opportunity per year. CMS anticipates the more frequent windows will greatly improve how technologies move through the adoption curve. The agency said additional details on the updated process will follow.

United States – October 23, 2026 -- Health2047, the venture studio of the American Medical Association, splits a marketing and communications executive's time 50/50 between its own brand and its portfolio startups, which range from obesity phenotyping to radiology AI.

Health2047 operates as an agency model, not just a fund

The studio builds and backs early-stage healthcare companies and supplies them with professional services instead of only writing checks. Its portfolio includes an obesity phenotyping company, a foundation model for radiologists and a physician-founded Medicare Advantage plan.

DALLAS – October 22, 2026 -- WeInfuse and Clarion have integrated AI phone agents directly into infusion provider and pharmacy operations, with Medix Infusion the first provider to use the connection.

Clarion agents read live WeInfuse order and authorization data

Clarion's agents see each patient's orders, prior authorization status and upcoming appointments in WeInfuse in real time. They resolve routine calls end to end and route everything else to the patient's clinic.

WeInfuse's cloud platform already manages intake, scheduling, clinical documentation, inventory management, dispensing and billing. The partnership adds the communications layer: inbound calls, scheduling requests, referral coordination and prescription refills, which the companies cite as growing administrative burdens as infusion therapy demand rises.

Global – October 22, 2026 -- Telix is soliciting partners across five areas of radiopharmaceutical development, with deal structures ranging from licensing and co-development to strategic M&A.

Telix targets therapeutic assets with established proof of concept

In therapeutics, Telix is looking for theranostic oncology programs in urologic and neurologic cancers, other solid tumors and hematologic malignancies. Candidates must have established proof of concept. Telix says they should benefit from its fully integrated radiopharmaceutical platform and strengthen its pipeline, platform and long-term growth.